Olof Karlsson

Biography

He served as CEO between 2001-10. Prior to joining Betagenon Dr Karlsson worked at Novartis. In the field of diabetes he was working in the international clinical team on the insulin secretagogue, nateglinide. He also participated in the business development, marketing and sales of nateglinide. He has also worked on other diabetes projects such as dipeptidyl peptidase IV inhibitors. He received his PhD in molecular biology at the University of Umeå where he studied cell-specific insulin gene transcription and postgraduate training at UCSF, USA.

Research Interest

Pharmaceutical Sciences